Chemical Engineering Journal, Journal Year: 2025, Volume and Issue: unknown, P. 163576 - 163576
Published: May 1, 2025
Language: Английский
Medicinal Research Reviews, Journal Year: 2023, Volume and Issue: 43(6), P. 2115 - 2176
Published: May 11, 2023
Abstract Breast cancer is the most malignant tumor in women, and there no absolute cure for it. Although treatment modalities including surgery, chemotherapy, radiotherapy are utilized breast cancer, it still a life‐threatening disease humans. Nanomedicine has provided new opportunity treatment, which focus of current study. The nanocarriers deliver chemotherapeutic agents natural products, both increase cytotoxicity against cells prevent development drug resistance. efficacy gene therapy boosted by nanoparticles delivery CRISPR/Cas9, Noncoding RNAs, RNAi, promoting their potential expression regulation. codelivery can exert synergistic impact on tumors enhance cellular uptake via endocytosis. Nanostructures able to induce photothermal photodynamic ablation cell death induction. provide microenvironment remodeling repolarization macrophages antitumor immunity. stimuli‐responsive nanocarriers, pH‐, redox‐, light‐sensitive, mediate targeted suppression tumors. Besides, diagnosis detect biomarkers. Various kinds have been employed therapy, carbon‐, lipid‐, polymeric‐ metal‐based nanostructures, different terms biocompatibility efficiency.
Language: Английский
Citations
100
Accounts of Chemical Research, Journal Year: 2024, Volume and Issue: 57(6), P. 905 - 918
Published: Feb. 28, 2024
ConspectusCancer vaccines have shown tremendous potential in preventing and treating cancer by providing immunogenic antigens to initiate specific tumor immune responses. An situ vaccine prepared from an autologous can mobilize a patient's own cell lysate as reservoir of antigens, thus triggering broad response diverse antitumor immunity individually tailored manner. Its efficacy is much better than that conventional with limited number epitopes. Several therapies, including radiotherapy (RT), chemotherapeutics, photodynamic therapy (PDT), photothermal (PTT) activate anticancer inducing death (ICD), the exposure tumor-associated (TAAs), cancerous testis neoantigens, danger-associated molecular patterns (DAMPs) low cost. However, immunogenicity dying cells low, making released DAMPs insufficient robust against malignant cancer. Moreover, immunosuppressive microenvironment (TME) severely hinders infiltration sensitization effector cells, causing tolerogenic immunological effects.Herein, we mainly focus on research developing nanoplatforms surmount major challenges met ICD-based vaccines. We first summarized variety nanotechnologies enable enhanced enhancing antigenicity adjuvanticity. The was obtained via regulating mode or state amplify recognition debris professional antigen-presenting (APCs). adjuvanticity potentiated raising level intensifying activity endogenous adjuvants promoting intelligent delivery exogenous immunostimulants recruitment promote antigen presentation. Additionally, versatile approaches reverse TME boost vaccination are also highlighted detail. On one hand, modulating metabolism TME, expansion versus be optimized improve efficiency other cellular components such reversing adverse phenotypes inhibiting interstitial significantly enhance immunotherapy effect. Finally, our viewpoint future opportunities this hopeful area presented. expect Account offer more insight into design, planning, development cutting-edge platforms, attention academic–industry collaborations, accelerating advanced progress vaccine-based clinic.
Language: Английский
Citations
25
Cell Reports Medicine, Journal Year: 2024, Volume and Issue: 5(3), P. 101432 - 101432
Published: Feb. 21, 2024
Dimeric prodrug nanoassemblies (DPNAs) stand out as promising strategies for improving the efficiency and safety of chemotherapeutic drugs. The success trisulfide bonds (-SSS-) in DPNAs makes polysulfide a worthwhile focus. Here, we explore comprehensive role tetrasulfide (-SSSS-) constructing superior DPNAs. Compared to disulfide bonds, endow with superlative self-assembly stability, prolonged blood circulation, high tumor accumulation. Notably, ultra-high reduction responsivity make highly selective "tumor bomb" that can be ignited by endogenous reducing agents cells. Furthermore, present an "add fuel flames" strategy intensify reductive stress at sites replenishing exogenous agents, making considerable progress inhibition. This work elucidates crucial establishing intelligent DPNAs, alongside combination methodology, propelling new heights potent cancer therapy.
Language: Английский
Citations
16
Biomaterials, Journal Year: 2024, Volume and Issue: 312, P. 122745 - 122745
Published: Aug. 3, 2024
Language: Английский
Citations
11
Aggregate, Journal Year: 2024, Volume and Issue: 5(3)
Published: Jan. 15, 2024
Abstract Ultrasound‐generated antigens combined with TLR7/8 agonists as adjuvants have demonstrated significant anti‐tumor efficacy an in‐situ vaccine. However, the use of can cause severe inflammatory responses. In this study, we present a novel tumor‐targeting nano‐adjuvant termed aPDL1‐PLG/R848 NPs, which are composed aPDL1 antibody, Fc‐III‐4C peptide linker (Fc‐linker) and poly( L ‐glutamic acid)‐ grafted ‐R848. Under ultrasound irradiation, antigen‐presenting cells activate immune mechanisms in vivo under dual stimulation situ adjuvants. The strategy inhibits primary tumor growth induces strong antigen‐specific memory effect to prevent recurrence vivo. This work offers safe potent platform for cancer vaccine based on therapy.
Language: Английский
Citations
10
Advanced Science, Journal Year: 2023, Volume and Issue: 10(15)
Published: April 5, 2023
Immune checkpoint blockade (ICB) therapies have had a tremendous impact on cancer therapy. However, most patients harbor poorly immunogenic tumor microenvironment (TME), presenting overwhelming de novo refractoriness to ICB inhibitors. To address these challenges, combinatorial regimens that employ chemotherapies and immunostimulatory agents are urgently needed. Here, combination chemoimmunotherapeutic nanosystem consisting of polymeric monoconjugated gemcitabine (GEM) prodrug nanoparticle decorated with an anti-programmed cell death-ligand 1 (PD-L1) antibody (αPD-L1) the surface stimulator interferon genes (STING) agonist encapsulated inside is developed. Treatment GEM nanoparticles upregulates PD-L1 expression in ICB-refractory tumors, resulting augmented intratumor drug delivery vivo synergistic antitumor efficacy via activation CD8
Language: Английский
Citations
21
Nano Today, Journal Year: 2024, Volume and Issue: 56, P. 102286 - 102286
Published: May 6, 2024
Language: Английский
Citations
7
Nano Letters, Journal Year: 2024, Volume and Issue: 24(24), P. 7432 - 7442
Published: May 20, 2024
Tumor immunotherapy has emerged as an efficacious therapeutic approach that mobilizes the patient's immune system to achieve durable tumor suppression. Here, we design a photodynamic therapy-motivated nanovaccine (Dex-HDL/ALA-Fe
Language: Английский
Citations
7
Small, Journal Year: 2024, Volume and Issue: 20(28)
Published: Feb. 11, 2024
Abstract In order to avoid the time‐consuming and laborious identification of tumor‐specific antigens (TSAs) during traditional vaccine fabrication process, a versatile photodynamic therapy (PDT)‐based method is developed construct whole‐tumor antigen tumor (TV) from surgically resected tissues for personalized immunotherapy. Mucoadhesive nanoparticles containing small‐molecular photosensitizer are fabricated directly co‐incubated with suspended cells obtained after cytoreduction surgery. After irradiation 405 nm laser, potent immunogenic cell death cancer could be induced. Along release TSAs, as‐prepared TV activate safe robust immune responses, leading efficient suppression postsurgery recurrence metastasis. The cannot only applied alone through various administration routes but also synergize immunoadjuvant, chemotherapeutics, checkpoint blockers exert more responses. This work provides an alternative way promote clinical translation PDT, which generally restricted by limited penetration light. Moreover, strategy facilitates application whole‐cell vaccines.
Language: Английский
Citations
6
Progress in Materials Science, Journal Year: 2024, Volume and Issue: 147, P. 101347 - 101347
Published: July 30, 2024
Language: Английский
Citations
6